Scott Schlachter, DO
Gastroenterology · Brick, NJNPI 1346213386
Payments from drug & device makers
Across 433 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$941
- Pfizer$440
- Takeda Pharmaceuticals U.S.A., Inc.$290
- Gilead$279
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$200%
- Grants$200%
- Food & beverage$6,24195%
- Education$2624%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 93 | $1,692 |
| AbbVie | 96 | $1,249 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 77 | $941 |
| Pfizer | 30 | $440 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $290 |
| Gilead | 20 | $279 |
| QOL Medical, LLC | 15 | $235 |
| Madrigal Pharmaceuticals | 10 | $154 |
| Mallinckrodt Hospital Products Inc. | 2 | $154 |
| Ferring Pharmaceuticals Inc. | 11 | $153 |
| Sanofi | 7 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $109 |
| Ironwood Pharmaceuticals, Inc | 7 | $94 |
| Bristol Myers Squibb | 6 | $87 |
| Merck | 5 | $69 |
| Alfasigma USA, Inc. | 5 | $65 |
| Nestle Healthcare Nutrition Inc. | 4 | $60 |
| Evoke Pharma, Inc. | 3 | $57 |
| Daiichi Sankyo Inc. | 4 | $52 |
| Lilly USA, LLC | 2 | $38 |
| Medtronic(2 entities) | 2 | $29 |
| Shire North American Group Inc | 2 | $25 |
| Novo Nordisk | 1 | $19 |
| Romark Laboratories, LC | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Celltrion USA Inc. | 1 | $15 |
| UCB, Inc. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Ardelyx, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Intercept Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,543 in reported general payments places this provider in the 75th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 26 | $668,161 |
| Humira(Cf) PenAdalimumab | 29 | $462,224 |
| OcalivaObeticholic Acid | 20 | $222,715 |
| CreonLipase/Protease/Amylase | 15 | $54,368 |
| XifaxanRifaximin | 17 | $45,466 |
| LinzessLinaclotide | 50 | $38,367 |
| Alosetron Hcl | 11 | $18,066 |
| TrulancePlecanatide | 19 | $13,816 |
| Dexlansoprazole DrDexlansoprazole | 33 | $10,056 |
| MovantikNaloxegol Oxalate | 13 | $5,039 |
| Pantoprazole Sodium | 333 | $4,915 |
| Omeprazole | 257 | $3,612 |
| Ursodiol | 21 | $3,411 |
| Mesalamine | 11 | $3,182 |
| CholestyramineCholestyramine (With Sugar) | 29 | $1,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,692 | $668,16126 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $13 | $222,71520 claims |
| AbbVieCreon, Linzess | $1,249 | $92,73565 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $941 | $59,28236 claims |
| Redhill Biopharma Inc.Movantik | $14 | $5,03913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Brick
- William BasriBrick$284K
- Mark CereficeBrick$25K
- Arkady BroderBrick$21K
- Kiran RaoSparta$1.3M
- Adekunle AdeotiIrvington$1.2M
- Carl WallachMorristown$766K
- Vinod RustgiNew Brunswick$697K
- Arvind TrindadeNew Brunswick$652K
- Barry KaufmanEgg Harbor Township$595K
- Promila BanerjeeStratford$522K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.